STOCK TITAN

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Edgewise Therapeutics (NASDAQ: EWTX), a muscle disease biopharmaceutical company, announced its upcoming presentation at the Annual Goldman Sachs Global Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025, at 3:20 pm ET. The event will be available through a live webcast on the company's Events & Presentations page, with replay access available for a limited time after the conference. Attendees are advised to connect several minutes before the presentation starts to ensure proper connection.
Edgewise Therapeutics (NASDAQ: EWTX), una società biofarmaceutica specializzata nelle malattie muscolari, ha annunciato la sua prossima presentazione alla Conferenza Annuale Goldman Sachs Global Healthcare. La presentazione è prevista per lunedì 9 giugno 2025 alle 15:20 ET. L'evento sarà trasmesso in diretta streaming sulla pagina Eventi e Presentazioni della società, con la possibilità di rivederlo per un periodo limitato dopo la conferenza. Si consiglia ai partecipanti di collegarsi alcuni minuti prima dell'inizio per assicurarsi una connessione corretta.
Edgewise Therapeutics (NASDAQ: EWTX), una compañía biofarmacéutica especializada en enfermedades musculares, anunció su próxima presentación en la Conferencia Anual Global de Salud de Goldman Sachs. La presentación está programada para el lunes 9 de junio de 2025 a las 3:20 pm ET. El evento estará disponible mediante una transmisión en vivo en la página de Eventos y Presentaciones de la compañía, con acceso a la repetición por tiempo limitado después de la conferencia. Se recomienda a los asistentes conectarse varios minutos antes del inicio para asegurar una conexión adecuada.
근육 질환 바이오제약 회사인 Edgewise Therapeutics(NASDAQ: EWTX)는 연례 골드만삭스 글로벌 헬스케어 컨퍼런스에서의 발표를 예고했습니다. 발표는 2025년 6월 9일 월요일 오후 3시 20분(동부시간)에 예정되어 있습니다. 이 행사는 회사의 이벤트 및 프레젠테이션 페이지를 통해 생중계되며, 컨퍼런스 후 일정 기간 동안 다시보기 서비스를 제공합니다. 참석자들은 원활한 연결을 위해 발표 시작 몇 분 전에 접속할 것을 권장합니다.
Edgewise Therapeutics (NASDAQ : EWTX), une société biopharmaceutique spécialisée dans les maladies musculaires, a annoncé sa prochaine présentation lors de la conférence annuelle Goldman Sachs Global Healthcare. La présentation est prévue pour le lundi 9 juin 2025 à 15h20, heure de l'Est. L'événement sera diffusé en direct via un webcast sur la page Événements et Présentations de la société, avec un accès au replay disponible pendant une durée limitée après la conférence. Il est conseillé aux participants de se connecter quelques minutes avant le début de la présentation afin de garantir une connexion optimale.
Edgewise Therapeutics (NASDAQ: EWTX), ein biopharmazeutisches Unternehmen für Muskelerkrankungen, gab seine bevorstehende Präsentation auf der jährlichen Goldman Sachs Global Healthcare Conference bekannt. Die Präsentation ist für Montag, den 9. Juni 2025, um 15:20 Uhr ET geplant. Die Veranstaltung wird per Live-Webcast auf der Seite des Unternehmens für Events & Präsentationen verfügbar sein, mit einer zeitlich begrenzten Wiederholungsmöglichkeit nach der Konferenz. Teilnehmer werden empfohlen, sich einige Minuten vor Beginn der Präsentation einzuwählen, um eine ordnungsgemäße Verbindung sicherzustellen.
Positive
  • None.
Negative
  • None.

BOULDER, Colo., June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET. 

The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedInX , Facebook and Instagram.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-annual-goldman-sachs-global-healthcare-conference-302470973.html

SOURCE Edgewise Therapeutics

FAQ

When is Edgewise Therapeutics (EWTX) presenting at the Goldman Sachs Healthcare Conference 2025?

Edgewise Therapeutics will present at the Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025, at 3:20 pm ET.

How can I watch the Edgewise Therapeutics (EWTX) Goldman Sachs conference presentation?

The presentation will be available via live webcast on Edgewise's Events & Presentations page, with replay access available for a limited time after the event.

What is Edgewise Therapeutics (EWTX) main business focus?

Edgewise Therapeutics is a biopharmaceutical company focused on developing treatments for muscle diseases.

Where can I find the replay of EWTX's Goldman Sachs Healthcare Conference presentation?

The presentation replay will be accessible on Edgewise Therapeutics' Events & Presentations page for a limited time following the conference.
Edgewise Therapeutics, Inc.

NASDAQ:EWTX

EWTX Rankings

EWTX Latest News

EWTX Stock Data

1.47B
82.28M
0.46%
111.04%
9.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOULDER